Bartsch, Rupert http://orcid.org/0000-0002-4384-6917
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 6 April 2021
Accepted: 14 April 2021
First Online: 30 April 2021
Conflict of interest
: R. Bartsch: advisory role: Astra-Zeneca, Celgene, Daiichi, Eisai, Eli-Lilly, MSD, Novartis, Pfizer, Pierre-Fabre, Puma, Roche, Samsung; lecture honoraria: Accord, Astra-Zeneca, BMS, Celgene, Eli-Lilly, Novartis, Pfizer, Pierre-Fabre, Roche, Sandoz; research support: Daiichi, MSD, Novartis, Roche.